Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BEHNAM KHALEGHI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1154306678
CMS profile
187884
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$4,374.10

187 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,275.10 186
Education $99.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BEHNAM KHALEGHI

NPI 1154306678 · CMS profile ID 187884

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154306678?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BEHNAM KHALEGHI, NPI 1154306678, CMS profile ID 187884. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154306678?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BEHNAM KHALEGHI, NPI 1154306678, CMS profile ID 187884. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154306678?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BEHNAM KHALEGHI, NPI 1154306678, CMS profile ID 187884, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1154306678?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

187 matching records · $4,374.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 187 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 187.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $12.9209/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224505388 CMS
Novartis Pharmaceuticals Corporation $33.2809/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264830 CMS
Novartis Pharmaceuticals Corporation $10.7009/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264836 CMS
AstraZeneca Pharmaceuticals LP $33.0409/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206419386 CMS
Novartis Pharmaceuticals Corporation $29.4809/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264828 CMS
PFIZER INC. $29.5009/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230337666 CMS
GlaxoSmithKline, LLC. $29.9009/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190596203 CMS
Fresenius Kabi USA, LLC $24.6408/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250529154 CMS
ABBVIE INC. $33.5208/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184609 CMS
Novartis Pharmaceuticals Corporation $23.6708/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264834 CMS
Amgen Inc. $28.4308/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228290494 CMS
Novartis Pharmaceuticals Corporation $34.9508/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264838 CMS
ABBVIE INC. $9.0308/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184607 CMS
Lilly USA, LLC $11.2208/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186525729 CMS
Janssen Biotech, Inc. $32.7308/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174728596 CMS
ABBVIE INC. $4.6508/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184605 CMS
AstraZeneca Pharmaceuticals LP $29.4908/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206974086 CMS
Novartis Pharmaceuticals Corporation $10.4808/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264832 CMS
GlaxoSmithKline, LLC. $26.9508/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190362436 CMS
Novartis Pharmaceuticals Corporation $23.8308/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264820 CMS
Amgen Inc. $5.8508/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227075941 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.1108/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223034084 CMS
UCB, Inc. $36.3608/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224505386 CMS
Amgen Inc. $24.8508/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228290492 CMS
Novartis Pharmaceuticals Corporation $27.7007/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264826 CMS
Lilly USA, LLC $30.5307/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186527065 CMS
Novartis Pharmaceuticals Corporation $10.7507/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264822 CMS
GlaxoSmithKline, LLC. $25.4107/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190602449 CMS
ABBVIE INC. $32.9007/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184603 CMS
Amgen Inc. $24.2907/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228290474 CMS
PFIZER INC. $32.9107/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229429027 CMS
ABBVIE INC. $34.7107/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184601 CMS
Janssen Biotech, Inc. $22.9307/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174730982 CMS
Alvogen Inc $18.2407/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1209952320 CMS
Lilly USA, LLC $11.2107/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186532201 CMS
ABBVIE INC. $16.1507/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184599 CMS
AstraZeneca Pharmaceuticals LP $23.1107/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206959435 CMS
SOBI, INC $17.7707/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240234092 CMS
GlaxoSmithKline, LLC. $26.9507/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190438266 CMS
ABBVIE INC. $27.9607/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184597 CMS
Amgen Inc. $17.3907/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228290508 CMS
UCB, Inc. $19.7907/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224505384 CMS
Radius Health, Inc. $34.4906/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249504560 CMS
Janssen Biotech, Inc. $33.2606/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174730697 CMS
Janssen Biotech, Inc. $2.8606/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174730745 CMS
Fresenius Kabi USA, LLC $29.8006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250529158 CMS
Lilly USA, LLC $28.7806/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186534501 CMS
Novartis Pharmaceuticals Corporation $29.1206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200264824 CMS
GlaxoSmithKline, LLC. $26.4706/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191814274 CMS
ABBVIE INC. $29.9506/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202184595 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,015.66 219
PY2020 $3,608.68 164
PY2021 $4,800.95 211
PY2022 $4,781.93 209
PY2023 $4,581.22 222
PY2024 $4,963.38 237
PY2025 $4,374.10 187

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $146,694.51 18
PY2024 Recipient $2,260.00 1
PY2024 Principal investigator $287,102.27 9
PY2023 Recipient $535.01 1
PY2023 Principal investigator $158,493.11 9
PY2022 Recipient $23,483.00 1
PY2022 Principal investigator $16,554.00 3
PY2020 Principal investigator $60,256.71 1
PY2019 Principal investigator $187.37 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,088.00 12/19/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619207
Principal investigator 1 Incyte Corporation $3,264.00 12/19/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619216
Principal investigator 1 Incyte Corporation $2,144.00 12/19/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619220
Principal investigator 1 Incyte Corporation $382.20 12/19/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619223
Principal investigator 1 Incyte Corporation $61.00 12/19/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619234
Principal investigator 1 Incyte Corporation $61.00 12/19/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619238
Principal investigator 1 Incyte Corporation $3,264.00 11/21/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619191
Principal investigator 1 Incyte Corporation $3,264.00 11/21/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619195
Principal investigator 1 Incyte Corporation $2,219.00 11/21/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619199
Principal investigator 1 Incyte Corporation $1,495.80 11/21/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619204
Principal investigator 1 Incyte Corporation $61.00 11/21/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619212
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619228
Principal investigator 1 Incyte Corporation $10,000.00 09/15/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619181
Principal investigator 1 Incyte Corporation $1,250.00 09/15/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619184
Principal investigator 1 Incyte Corporation $1,000.00 09/15/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240619187
Principal investigator 1 Eli Lilly and Company $62,329.00 05/23/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS LLC
A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL No dispute reported 06/30/2026 1187891568
Principal investigator 1 Eli Lilly and Company $547.51 01/30/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187893654
Principal investigator 1 Eli Lilly and Company $53,095.00 01/07/2025 Non-covered Recipient Entity
WOLVERINE CLINICAL TRIALS LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187893908